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Background: Endocrine function in psychiatric patients may be affected by mental disorder itself as well as by
antipsychotic medications.
The aim of this naturalistic observational study was to determine if treatment of acute psychotic episode with
antipsychotic medication affects thyroid axis hormone concentrations and if such changes are associated with
symptomatic improvement.
Methods: Eighty six adult acute psychotic patients, consecutively admitted to a mental hospital, were recruited for
the study. All patients were physically healthy and without thyroid disease. During the hospitalization period all
study patients received treatment with antipsychotic medication according to clinical need. Severity of the
psychotic episode was evaluated using the Brief Psychiatric Rating Scale (BPRS) and venous blood samples were
drawn for analysis of free triiodothyronine (FT3), free thyroxine (FT4), and thyroid stimulating hormone (TSH)
concentrations on the day of admission and on the day of discharge from the hospital.
Results: Antipsychotic drug treatment was associated with decrease of mean FT3 (p < 0.001) and FT4 (p = 0.002)
concentrations; and with increase of mean TSH (p = 0.016) concentrations. Changes in thyroid hormone
concentrations were mostly predicted by baseline hormone concentrations. Individual changes were not limited to
decrease in high hormone concentrations; in patients who had low FT3 or FT4 concentrations, treatment resulted
in increase in concentrations. Such an increase was established in one-quarter of patients for FT3 concentrations
and in one-third of patients for FT4 concentrations. Fall in FT4 concentrations negatively correlated with the
improvement in the BPRS score (r = −0.235, p = 0.023).
Conclusions: The study indicates that antipsychotic treatment resulted in a decrease in mean FT3 concentrations
and in an increase in mean TSH concentrations after recovery from acute psychosis. Symptomatic improvement
was less evident in patients who experienced a decrease in FT4 concentrations.
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Acute psychoses, including schizophrenia, have a life time
prevalence of 2–3% in the general population [1]. Patients
suffer decrease in social functioning and quality of life,
and society suffers a huge economic burden [2].
Endocrine function in psychiatric patients may be
affected by mental disorder itself as well as by medications.
Neuro-endocrine abnormalities have received significantly
less attention in psychotic disorders relative to affective
disorders [3]. In acute psychotic episodes [4] as well as in
chronic schizophrenia [5,6] changes in thyroid function and
thyroid autoimmunity have been reported. Elevated serum
thyroxine (T4) concentrations with or without decrease in
triiodothyronine (T3) concentrations have been found in
acute schizophrenic patients [7] as well as in patients with
other severe mental disorders, such as acute major depres-
sion and mania [8-10]. In our recent cross-sectional study
[11], we have confirmed that patients with acute psychosis
upon admission to the hospital had elevated T4 concentra-
tions, especially patients who were free from treatment with
antipsychotics. This syndrome of elevated T4 concentra-
tions in acutely psychotic patients is coined as transient
hyperthyroxinemia because it usually resolves during
recovery from a psychotic episode [12,13]. However, the
majority of schizophrenic patients appear to be euthyroid
with normal thyroid stimulating hormone (TSH) concen-
tration and normal TSH response to thyrotropin-releasing
hormone (TRH) challenge [14,15].
Studies examining the possible effects of antipsychotic
treatment on thyroid axis function in psychotic patients
are limited to reports on recuperation from the hyperthyr-
oxinemia [16-18]. Data on the effects of antipsychotic
treatments on T3 and TSH concentrations are scant and
data on the associations between changes in thyroid
hormone concentrations and mental status are lacking.
In the light of the above observations, we have set out a
naturalistic study in acute psychotic patients aiming to
determine (1) if antipsychotic treatment affects thyroid
axis hormone concentrations and (2) if changes in thyroid
axis hormone concentrations after antipsychotic treatment
are associated with symptomatic improvement.
Methods
Study population
During a two year period adult acute psychotic patients,
consecutively admitted to the acute psychosis department
of the District Mental Hospital in Kaunas, Lithuania, were
screened for eligibility to participate in the prospective
interventional study (EudraCT No. 2007-001541-18; study
results not published). Patients not meeting the inter-
ventional study criteria were invited to participate in this
prospective naturalistic observational study if they were
able to understand the study aims and procedures. The
protocol and informed consent form of the study wereapproved by the Lithuanian Bioethics Committee and each
study patient had signed a written informed consent form.
One hundred and four psychotic patients aged from 18
to 70 years old with no significant or unstable medical
conditions, and physically healthy based on the physical
examination, past medical history, and results of routine
blood and urine tests, were invited to participate in the
study. Exclusion criteria for the study were: any significant
and/or unstable somatic condition, a history of epileptic
seizures, suicidal tendencies or severe agitation, a history of
substance or drug dependence within 6 month of the
screening visit, treatment for concurrent somatic condition
during the psychosis treatment period, treatment with
long-acting antipsychotics during the four month period
before the hospital admission, or electroconvulsive therapy
during the three month period before the admission. Eight
patients were excluded from the study due to thyroid
dysfunction at baseline: six patients had TSH concentra-
tions higher than 4.05 μIU/ml suggesting hypothyroidism
and two patients had TSH concentration lower than
0.17 μIU/ml suggesting hyperthyroidism. We have also
excluded seven patients who had thyroid peroxidase anti-
body (TPOAb) concentrations higher than 20 IU/ml,
suggesting possible autoimmune thyroid disease. Further-
more, three patients did not receive treatment with anti-
psychotic medications during the hospitalization period
and were excluded from the analyses. Therefore, 86 (83%)
acute psychotic patients (43 men and 43 women, mean age
36 years) comprised the study sample and were studied.
Thirty patients were admitted for their first psychotic
episode and 56 patients have experienced relapsed psych-
otic episode. In relapsed patients, the duration since their
previous psychotic episode averaged five years. Mean
treatment duration for the current psychotic episode was
29 days (range from 4 days to 55 days).
Following a naturalistic design of the study, patients
were treated according to the usual clinical practice and
there were no restrictions for psychiatric treatment(s)
selection. All 86 patients were treated with antipsychotic
medication (41 patients with haloperidol, 16 with risperi-
done, 14 with olanzapine, 5 with quetiapine, 6 with
amisulpiride, 3 with ziprazidone, and 1 with tiapride); 83
patients were treated with benzodiazepines (diazepam,
clonazepam, or lorazepam); and 25 patients were treated
with antidepressants (amitriptyline, sertraline, paroxetine,
escitalopram, or venlafaxine). With regards to combined
psychiatric treatment, 59 patients received antipsychotic
medication and benzodiazepines, 24 patients – anti-
psychotic medication, antidepressant and benzodiazepines,
2 patients – antipsychotic medication only, and 1 patient –
antipsychotic medication and antidepressant.
The control group consisted of 120 consecutive blood
donors recruited from the Kaunas Blood Donors Center,
Lithuania. All blood donors were evaluated according to the
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were considered as being healthy, with no history of past or
present clinical psychiatric disorder or unstable medical
condition; and without current use of medication, including
psychiatric drugs. Five blood donors with elevated TSH
concentration were excluded from the analysis and there
were no subjects with suppressed TSH concentrations. We
have excluded six blood donors with TPOAb concentrations
higher than 20 IU/ml. Therefore blood samples from 109
control subjects (66 men and 43 women, mean age 34 years)
were used for biochemical comparisons.
Psychiatric evaluations
Psychiatric diagnoses were established according to the
Diagnostic and Statistical Manual of Mental Disorders, 4th
Edition, Text Revision (DSM-IV-TR) diagnostic criteria [19]
using the MINI-Plus 5.0.0 structured clinical interview [20]
for all study patients but not for the control group. The
MINI is designed as a brief structured interview for the
diagnoses of major Axis I psychiatric disorders according to
the DSM-IV-TR criteria. The MINI-Plus is comparable
with other standard diagnostic instruments, such as the
Structured Clinical Interview for DSM-IV (SCID) [21] or
Composite International Diagnostic Interview (CIDI) [22].
The MINI is a reliable instrument and can be administered
faster than the SCID or CIDI. The MINI-Plus is divided
into 26 modules, identified by letters, each corresponding
to a diagnostic category, pertaining to past and current
diagnoses of mental disorders. At the beginning of each
diagnostic module (except for the psychotic disorders
module), screening questions corresponding to the main
diagnostic criteria of the disorder are presented. At the end
of each module, a diagnostic box permits the clinician to
indicate whether diagnostic criteria for a specific mental
disorder have been met.
We have used three modules of the MINI-Plus address-
ing diagnoses of the major depressive episode (module A),
(hypo) manic episode (module D), and psychotic disorders
(module M). Patients who met the diagnostic criteria for
the current psychotic disorder were included in the study.
Diagnostic algorithms for psychotic disorders were used
to specify diagnosis of the psychotic disorder. Forty-six
patients were diagnosed as having schizophrenia; 18
patients, brief psychotic disorder; 13 patients, schizoaffective
disorder; 5 patients, schizophreniform disorder and 4
patients, affective psychosis.
Severity of the psychotic disorder was assessed by using
the Brief Psychiatric Rating Scale (BPRS) before and after
acute psychosis treatment. The BPRS assesses severity of
18 symptom constructs that are rated from 0 (symptom
not present) to 6 (symptom is extremely severe) and
includes positive, negative and general psychopathology
symptoms. The BPRS is useful in gauging treatment effi-
cacy of psychotic disorders [23]. The BPRS is administeredby a clinician with knowledge of psychotic disorders and
ability to interpret the constructs used in the assessment.
Some items (e.g. mannerism and posturing) are based on
the observation of the patient‘s behavior; other items (e.g.
anxiety) involve self-reporting by the patient. Family
members can also provide information regarding symptoms.
Total BPRS score ranges from 0 to 108. Scores below 10 are
considered as normal variations. For treatment efficacy
analysis we used the change in the total BPRS scores by
subtracting BPRS scores after treatment from BPRS scores
before treatment. All diagnostic evaluations were made by a
trained psychiatrist (VS).Endocrine measurements
Venous blood samples were drawn on two occasions: after
overnight fast at 8 A.M. on the morning after admission
to the hospital and on the day of discharge. Blood was
centrifuged, and serum was frozen for storage at −40°C.
All samples were analyzed for hormone concentrations
simultaneously to avoid inter-assay variability.
Serum free T3 (FT3), free T4 (FT4), TSH, and TPOAb
concentrations were assessed by radioimmunoassay, using
commercial IMULITE kits (Czech Republic). Sensitivity of
the FT3 assay was 0.5 pmol/l; FT4, 0.4 pmol/l; TSH,
0.025 μIU/l, and TPOAb, 2 IU/ml. The normal reference
interval for FT3 concentrations was 3.5-6.9 pmol/l; for
FT4, 12.4-21.2 pmol/l; for TSH, 0.17-4.05 μIU/ml; and for
TPOAb, >20 IU/ml.Statistical analyses
Kolmogorov-Smirnov statistics showed normal distribution
of all variables; therefore, parametric statistical tests were
used. Distributions of age, BPRS scores, and FT4, FT3 and
TSH concentrations were expressed as mean ± SD.
To evaluate significance of change in hormone concen-
trations and in BPRS scores before and after treatment
with antipsychotics, paired t-tests were used. Change was
expressed as difference (Δ) between values after treatment
(on the last day before discharge) minus values at baseline
(on hospital admission). To evaluate differences in FT3,
FT4 and TSH concentrations in patients before and after
treatment versus control group, unpaired t-tests were used.
Differences were considered as statistically significant when
p < 0.05.
Differences in changes of thyroid axis hormone concen-
trations before versus after the treatment (ΔFT3, ΔFT4,
ΔTSH) as a function of antidepressant treatment (used
versus not used) and antipsychotic class (typical versus
atypical) were evaluated by using unpaired t-tests. Possible
impact of different antipsychotic medication on thyroid
hormone concentrations (1) before treatment, (2) after
treatment and (3) before versus after treatment was evalu-
ated using the ANOVA analyses with thyroid hormone
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medication as independent variable.
To evaluate associations between pre-treatment FT3, FT4
and TSH concentrations and post-treatment change in
respective hormone concentrations (ΔFT3, ΔFT4, ΔTSH)
the univariate and multivariate linear regression models
were performed. In multivariate models, gender, age, dur-
ation of hospitalization, number of past psychotic episodes,
duration of the disease, baseline BPRS scores, antidepressant
and benzodiazepine treatments during the hospitalization,
antipsychotic used during the hospitalization and upon
admission together with baseline hormone concentrations
were considered as independent variables and changes
in hormone concentrations as dependent variables. Data
analyses were performed using the SPSS statistical software
(version 17.0).
Results
Upon admission to the hospital all 86 patients had TSH
concentrations within the normal range because such was
an inclusion criterion. Nevertheless 10 patients had elevated
FT4 concentrations indicating euthyroid hyperthyroxinemia.
There were no statistically significant differences between
patients and control group subjects according to age and
gender; however, there were significant differences in
thyroid axis hormone concentrations. As shown in Table 1,
mean FT3 concentrations (not different from controls
before treatment) decreased after psychosis treatment with
antipsychotics (p < 0.001) and became significantly lower
compared to controls (p < 0.001). Mean FT4 concentrations
also decreased significantly (p = 0.002) after antipsychotic
treatment. However, in contrast to FT3 concentrations,
mean FT4 concentrations, being increased before treatment
(p = 0.004), became not different from controls after
treatment.
After treatment with antipsychotics TSH concentrations
remained in euthyroid range in 81 (94%) patients, and
increased above the normal range (>4.05 μIU/ml) in five
patients, suggesting possible hypothyroidism. However, FT3
and FT4 concentrations in those five patients remained
within the normal range. In all the study patients mean
TSH concentrations increased after treatment (p = 0.016)
and remained significantly higher compared to controlsTable 1 Psychiatric symptoms and thyroid axis hormone conc
treatment, and in healthy blood donor controls, Mean ± SD





Brief Psychiatric Rating Scale 39 ± 8 19 ± 6 p <
Free triiodothyronine (pmol/l) 5.2 ± 1.0 4.5 ± 1.0 p <
Free thyroxine (pmol/l) 17.9 ± 3.1 16.8 ± 2.6 p =
Thyroid stimulating hormone (μIU/ml) 1.68 ± 0.9 2.07 ± 1.4 p =(p < 0.001). There were no significant differences in
changes of thyroid axis hormones concentrations before
versus after the treatment period as a function of anti-
depressant use and antipsychotic class (Table 2). There
were no statistically significant differences in thyroid
hormone concentrations before treatment, after treatment
and before versus after treatment as a function of different
antipsychotic medication (all p-values ≥ 0.34; data not
shown).
We found no significant associations between baseline
hormone concentrations and improvement in psychotic
symptoms. However, change in FT4 concentrations
negatively correlated with change in BPRS score (r =−0.235
and p = 0.023) (Figure 1). There were no significant
correlations between changes of thyroid axis hormone con-
centrations, but changes in TSH concentrations correlated
positively with changes in FT3 concentrations (r = 0.297
and p = 0.004) (Figure 2).
Univariate linear regression analyses revealed strong
associations between baseline hormone concentrations
and change in respective hormone concentrations after
antipsychotic treatment, with baseline FT3 concentrations
and baseline FT4 concentrations accounting for 42% and
44% of their change, respectively. An association between
baseline TSH concentration and the change in TSH
concentration accounted for only 16% of the variance
(Figure 3).
In multivariate linear regression models (Table 3)
baseline FT3 concentrations accounted for 48% of the
ΔFT3 variance, with gender being the second strongest
predictor. Baseline FT4 concentrations accounted for 51%
of the ΔFT4 variance, with number of psychotic episodes,
baseline BPRS scores, antipsychotic used upon and during
hospitalization being other significant factors. Baseline
TSH values were the only significant correlates of changes
in TSH concentrations.
Effects of treatment with antipsychotics were not limited
to decrease in elevated thyroid hormone concentrations.
In some patients it resulted in an increase of low hormone
concentrations. Such an increase occurred in one-quarter
of patients for FT3 concentrations (n = 23) and in
one-third of patients for FT4 concentrations (n = 29)
(Figure 4).entrations in acute psychotic patients before and after
(paired t-test) Controls p (unpaired t-test)




0.001 – – –
0.001 5.2 ± 0.9 0.70 <0.001
0.002 16.8 ± 2.2 0.004 0.89
0.016 1.40 ± 0.7 0.016 <0.001
Table 2 Changes (Δ) in thyroid axis hormone
concentrations as a function of psychiatric medication





Antidepressants Used Not used
N = 25 N = 61
ΔFT3 (pmol/l) 0.42 ± 0.96 0.76 ± 1.31 0.425 0.675
ΔFT4 0.47 ± 2.77 1.41 ± 3.43 2.138 0.074




N = 42 N = 44
ΔFT3 0.85 ± 1.15 0.49 ± 1.27 0.507 0.813
ΔFT4 1.09 ± 3.49 1.18 ± 3.07 1.736 0.086
ΔTSH −0.44 ± 1.55 −0.34 ± 1.39 −0.335 0.738
*Controlled according age (years), gender.
Figure 2 An association between post-treatment change in free
triiodothyronine (ΔFT3) and in thyroid stimulating hormone
(ΔTSH) concentrations in 86 acute psychotic patients.
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In this study we have found significant changes in thyroid
axis hormone concentrations after treatment for acute
psychotic episode with antipsychotic drugs. We confirmed
that antipsychotic treatment results in recuperation of
euthyroid hyperthyroxinemia that was present at the time
of admission. However, the decrease in FT4 concentrations
was associated with less improvement in psychotic
symptom severity. In addition, we have reported the novel
finding that antipsychotic treatment resulted in decrease of
mean FT3 concentrations and in increase of mean TSH
concentrations.
Our finding that FT4 concentrations decreased to normal
level after antipsychotic treatment is in line with earlier
findings of others regarding total T4 concentrations [18,24].
For example, Kelly and Conley [24] assessed thyroid
function in 38 adult treatment-resistant schizophrenicFigure 1 An association between post-treatment change in free
thyroxine (ΔFT4) concentrations and in the Brief Psychiatric
Rating Scale (ΔBPRS) scores in 86 acute psychotic patients.patients after six weeks of treatment with various antipsy-
chotics. They have found little change in thyroid axis func-
tion, with an exception of a significant decrease in total T4
serum concentrations in patients taking quetiapine. The au-
thors suggested that the decrease in total T4 concentrations
during quetiapine treatment may be related to competitive
metabolism of thyroid hormones and quetiapine by liver en-
zymes. In our study, the effect of quetiapine (seven patients)
on thyroid axis hormone concentrations was similar to other
antipsychotic drugs. We think that in the drug resistant pa-
tients studied by Kelly and Conley [24] sluggishness of thy-
roid axis function to respond to antipsychotic drugs may
have been an endocrine expression of treatment resistance.
In the studies of Baumgartner et al. [18] and Kelly and
Conley [24] significant changes were confined to T4 concen-
trations. Changes in other thyroid axis hormone concentra-
tions were not significant. By contrast, in the present study
significant changes in T3 and TSH concentrations were also
noted. This apparent inconsistency may be explained, at
least in part, by our larger sample size allowing to reveal an
array of dynamics between the thyroid axis variables and
mental state.
Regarding all three thyroid axis hormones that we mea-
sured, changes in their concentrations after treatment were
mostly predicted by concentrations at baseline. It is import-
ant to note that changes were not limited to decrease of
high concentrations; in a significant proportion of patients
increase of low concentrations occurred. Taken together,
these two sets of findings suggest stabilization of thyroid
axis function after recovery from acute psychosis. The clin-
ical meaning of such thyroid hormone stabilizing effect
needs clarification. It may be explained as a simple regres-
sion to the mean, the mean having been skewed by the
event of acute psychosis. However, if regression to the
mean were the only dynamic at work, values of all three
Figure 3 Associations between baseline and post-treatment change (Δ) in free triiodothyronine (FT3), free thyroxine (FT4) and thyroid
stimulating hormone (TSH) concentrations in 86 acute psychotic patients.
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ion. The notion of regression to the mean fits well for FT4
concentrations but not for FT3 and TSH concentrations.
When compared to healthy blood donors, in psychoticpatients mean FT4 concentrations being high before treat-
ment returned to the normal range after treatment. In con-
trast, mean FT3 concentrations, being in the normal range
before treatment, decreased significantly and fell below the
Table 3 Multivariate linear regression models with









Gender (men/women) -.262 -.068 -.028




Number of past psychotic
episodes
.081 .241 -.026





















R2 0.48 0.51 0.06
*p < 0.1.
Δ, value after treatment minus baseline.
Statistically significant (p-value < 0.05) β-values are presented in bold.
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after treatment remained significantly higher in psychotic
patients relative to the control group. This assembly of ef-
fects suggests that more than regression to the mean was











Decrease or no change Increase
Figure 4 Distribution of changes in free triiodothyronine (FT3),
free thyroxine (FT4) and thyroid stimulating hormone (TSH)
concentrations in 86 acute psychotic patients in response
to treatment.drugs. A similar conclusion was reached by Baumgartner
et al. [18] that thyroid function may be altered as a direct
consequence of antipsychotic drug treatment.
After evaluating a relationship of changes in thyroid axis
hormone concentrations with changes in symptom severity
we did not replicate findings of Baumgartner and colleagues
[18] who have reported that thyroid hormone concentra-
tions before treatment predicted treatment response. In our
study, improvement in BPRS scores was negatively, not
positively, associated with the magnitude of changes in FT4
concentrations; the more FT4 concentrations decreased,
the less improvement in mental symptoms was achieved.
These discrepancies may be explained by some methodo-
logical differences between the two studies. Baumgartner
et al. [18] measured total T4 concentrations (most of which
is bound) while we measured free T4. Gabay and Kushner
[25] reported that thyroid hormone binding proteins are
acute phase proteins. Inflammation plays a role in acute
psychosis [26] and may affect protein bound hormone con-
centrations. Therefore, measurement of total T4 concentra-
tions may capture immune as well as endocrine changes,
while free T4 is more likely to reflect endocrine changes
unalloyed by co-existing immune processes.
In the present study, the fall of FT4 concentrations, but
not FT3 concentrations, was associated with worse
treatment outcome. Low T3 concentration is a laboratory
manifestation of the sick euthyroid syndrome that is preva-
lent in psychiatric patients [27,28]. Thyroid hormone con-
centrations, including a manifestation of the sick euthyroid
syndrome, are associated with genetic polymorphisms of
thyroid axis enzymes involved in the metabolism of thyroid
hormones. For example, a study led by Cooper-Kazas et al.
[28] has found that low T3 concentrations in patients with
major depression were associated with polymorphism in
the DIO1 gene encoding type-1 deidionase, an enzyme
responsible for conversion of T4 to the more active T3 in
peripheral tissues. Since our study provided no genetic data,
we can only speculate that genetic polymorphism in thyroid
axis proteins, such as DIO1, and/or elevated activity of
type-1 deidionase may have partially accounted for the
observed findings regarding the association of FT3 and FT4
concentrations with treatment outcome.
Considering how antipsychotic drugs may exert their
effects on the thyroid axis we must enter the caveat that we
cannot separate drugs effects from what might be called
simply the effects of improvement because almost all our
patients improved and all had taken drugs. Inspection of
Figure 3 shows that none of the endocrine variables
measured changed in the same way, or even in the same
direction. Clearly there are subgroups. In a main, our
patients overtime decreased concentrations of thyroid
hormones and increased TSH concentrations. One could
simply say that drug treatment damped hyperthyroxinemia
caused by psychosis and that this in turn diminished the
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On the other hand we have found a positive correlation
between change in FT3 concentrations and change in TSH
concentrations, suggesting other effects of antipsychotics on
thyroid axis function.
At the cellular level a classical effect of antipsychotics is
to block the action of the dopamine. This blockade may
have consequences for the thyroid axis, because dopamine
exerts tonic inhibition on pituitary TSH secretion. Thus,
antipsychotics blocking the inhibition effects caused by
dopamine may enhance TSH secretion. This in turn may
stimulate T3 production by the thyroid gland and by
peripheral tissues [29]. This arrangement may explain the
positive correlation between magnitude of change in
FT3 concentrations and magnitude of change in TSH
concentrations.
A limitation of our study is the absence of patients
without antipsychotic treatment (placebo group), not
allowing us to determine if changes in thyroid axis
function are caused by treatment with antipsychotics or
by remission of psychosis itself. Lack of genetic informa-
tion on thyroid axis related proteins and morphological
assessment of the thyroid gland are another limitations.
Finally, the absence of a control procedure in the control
subjects precluded from investigating the degree of
thyroid hormone variability in the control group subjects.
Thus, subsequent studies should consider including a
control procedure in the control group subjects in order
to demonstrate normal thyroid hormone variability.
However, our relatively large sample size allowed us to
describe thyroid axis hormone variation patterns in
response to treatment with antipsychotics. Our finding
that such a treatment results in a decrease in FT3
concentrations is new and needs attention. Low T3
concentrations were reported in depressed patients [8],
and compensation of this syndrome with exogenous T3
resulted in augmentation of antidepressive response at
least in patients with DIO1 polymorphism [28].
Conclusions
The study indicates a decrease in mean FT3 concentrations
and an increase in mean TSH concentrations after recovery
from acute psychosis. Symptomatic improvement is less
expressed in patients who experience a decrease in FT4
concentrations.
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